specialty pharma
Aspen’s baffling ailment
The group’s swift descent from market darling to pariah has been as painful as it is perplexing, debt woes aside
22 August 2019 - 05:00
The market diagnosis for Aspen Pharmacare looks dire. In the past month the group’s shares have shed almost 30%. Over six months the share price is down about 50%, and over three years a stomach-churning 80%.
These are not the vital signs investors would associate with one of the top-performing JSE blue-chip counters over the past two decades. Worries about its debt aside, the share price movements suggest there is an underlying fear that Aspen’s results for the year to end-June might throw out a few operational ailments...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.